NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
20.43
+0.42 (2.10%)
Nov 21, 2024, 12:19 PM EST - Market open
NAMS Employees
NewAmsterdam Pharma Company had 29 employees as of December 31, 2023. The number of employees increased by 12 or 70.59% compared to the previous year.
Employees
29
Change (1Y)
12
Growth (1Y)
70.59%
Revenue / Employee
$1,158,414
Profits / Employee
-$6,859,172
Market Cap
1.89B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 12 | 70.59% |
Dec 31, 2022 | 17 | - | - |
Related Stocks
Company Name | Employees |
---|---|
CONMED | 4,000 |
iRhythm Technologies | 2,000 |
LeMaitre Vascular | 630 |
Arrowhead Pharmaceuticals | 525 |
Geron | 141 |
Keros Therapeutics | 136 |
IDEAYA Biosciences | 124 |
CG Oncology | 61 |
NAMS News
- 2 days ago - NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - GlobeNewsWire
- 19 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - GlobeNewsWire
- 6 weeks ago - Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga
- 4 months ago - NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors - GlobeNewsWire